TVGN TEVOGEN BIO HOLDINGS INC

Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Join Startup Forum Panel at Databricks DATA + AI World Tour in Boston

Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Join Startup Forum Panel at Databricks DATA + AI World Tour in Boston



WARREN, N.J., Sept. 10, 2025 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ), today announced that Mittul Mehta, Chief Information Officer of Tevogen and Head of Tevogen.AI, will participate as a panelist in the Startup Forum at the Databricks DATA + AI World Tour on October 8, 2025.

The Startup Forum will feature insights from venture capital leaders and early-stage innovators on how they are scaling their companies with Databricks. Mehta will join industry peers including Chris Gervais, CTO of Codametrix, and Stavros Papadopoulos, CEO of TileDB, in a discussion moderated by Tony Pezzullo, Principal at SignalFire. Mehta will share perspectives on Tevogen.AI’s application of advanced data and AI technologies, including its PredicTcell™ platform, developed in collaboration with Microsoft and Databricks, to accelerate precision immunotherapy development.

Databricks DATA + AI World Tour will take place at the Sheraton Boston Hotel. For more information please contact,

Contacts

Tevogen Bio Communications

T: 1 877 TEVOGEN, Ext 701

A photo accompanying this announcement is available at



EN
10/09/2025

Underlying

TVGNTEVOGEN BIO HOLDINGS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on TEVOGEN BIO HOLDINGS INC

 PRESS RELEASE
Free
TVGN TEVOGEN BIO HOL...

Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a ...

Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Contract Research Organization WARREN, N.J., Feb. 27, 2026 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ) today announced that it has entered into a signed, non-exclusive, non-binding Letter of Intent (“LoI”) to evaluate a potential transaction with a distinguished global Contract Research Organization (“CRO”). If consummated, the proposed transaction could expand Tevogen’s clinical development capabilities and could support the Company’s evolution into a revenue-generating healthcare enterp...

12h / 27m 1 EN
 PRESS RELEASE
Free
TVGN TEVOGEN BIO HOL...

UPDATE - Tevogen Signs Letter of Intent to Evaluate Potential Acquisit...

UPDATE - Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of Sciometrix and its Digital Care Management Platform Clinicus WARREN, N.J. and ROYAL OAK, Mich., Feb. 26, 2026 (GLOBE NEWSWIRE) --   (“Tevogen Bio Holdings Inc.”) (Nasdaq: ) today announced that it has entered into a signed, non-exclusive, non-binding Letter of Intent (“LoI”) to evaluate a potential transaction with (“Sciometrix”), a privately held healthcare technology and value-based care solutions provider headquartered in Michigan and developer of the Clinicus digital care management platform, that would, if ...

February 26, 2026 1 EN
 PRESS RELEASE
Free
TVGN TEVOGEN BIO HOL...

Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of Sc...

Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of Sciometrix and its Digital Care Management Platform Clinicus WARREN, N.J. and ROYAL OAK, Mich., Feb. 26, 2026 (GLOBE NEWSWIRE) --   (“Tevogen Bio Holdings Inc.”) (Nasdaq: ) today announced that it has entered into a signed, non-exclusive, non-binding Letter of Intent (“LoI”) to evaluate a potential transaction with (“Sciometrix”), a privately held healthcare technology and value-based care solutions provider headquartered in Michigan and developer of the Clinicus digital care management platform, that would, if consummat...

February 26, 2026 1 EN
 PRESS RELEASE
Free
TVGN TEVOGEN BIO HOL...

Tevogen Board to Evaluate Potential One-Time Special Cash Dividend to ...

Tevogen Board to Evaluate Potential One-Time Special Cash Dividend to Shareholders WARREN, N.J., Jan. 30, 2026 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ) today announced that its Board of Directors has expressed its intention to evaluate the potential declaration of a one-time special cash dividend to shareholders, contingent upon the achievement of specified financial milestones to be determined at a future date, which could include revenue and earnings targets. Any consideration of a special dividend would be subject to the Company’s future financial per...

January 30, 2026 1 EN
 PRESS RELEASE
Free
TVGN TEVOGEN BIO HOL...

Tevogen to Align Long-Term Stock-Based Incentive Program With Company ...

Tevogen to Align Long-Term Stock-Based Incentive Program With Company Milestones, Including Revenue WARREN, N.J., Jan. 29, 2026 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ), today announced that the current time- and individual performance-based long-term stock incentive program will be modified to align awards with defined company milestones including revenue. The updated program will be applicable to all employees, officers, directors and consultants who are eligible to participate in the Company’s long term incentives plan. Tevogen Founder and CEO, Dr. Ry...

January 29, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch